Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc (ACXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,163
  • Shares Outstanding, K 16,893
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,580 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta -1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.03
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.09
  • Most Recent Earnings $-0.17 on 11/12/24
  • Next Earnings Date 11/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 644.26% ( +116.63%)
  • Historical Volatility 127.90%
  • IV Percentile 96%
  • IV Rank 76.63%
  • IV High 838.81% on 12/06/24
  • IV Low 6.51% on 10/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 1,186
  • Open Int (30-Day) 911

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +52.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7200 unch
on 12/18/24
1.7300 -58.38%
on 11/20/24
-0.9800 (-57.65%)
since 11/18/24
3-Month
0.7200 unch
on 12/18/24
2.2000 -67.27%
on 10/04/24
-1.2500 (-63.45%)
since 09/18/24
52-Week
0.7200 unch
on 12/18/24
5.2800 -86.36%
on 01/12/24
-2.7500 (-79.25%)
since 12/18/23

Most Recent Stories

More News
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule...

ACXP : 0.7200 (-16.63%)
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule...

ACXP : 0.7200 (-16.63%)
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

THAR : 2.10 (-3.67%)
ACXP : 0.7200 (-16.63%)
UBI.AX : 0.125 (unch)
GRF.VN : 0.480 (-4.00%)
WISA : 1.6900 (-1.17%)
NNVC : 1.5000 (+0.67%)
ALCO : 25.85 (-1.49%)
MYPS : 1.98 (-5.71%)
ABL : 7.55 (-1.95%)
PERF : 2.13 (-6.17%)
PETV : 0.4015 (unch)
ABEO : 5.63 (-4.25%)
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

ESGH.TO : 29.84 (-0.23%)
THAR : 2.10 (-3.67%)
ACXP : 0.7200 (-16.63%)
GRF.VN : 0.480 (-4.00%)
WISA : 1.6900 (-1.17%)
ALCO : 25.85 (-1.49%)
NNVC : 1.5000 (+0.67%)
ABL : 7.55 (-1.95%)
MYPS : 1.98 (-5.71%)
PERF : 2.13 (-6.17%)
PETV : 0.4015 (unch)
ABEO : 5.63 (-4.25%)
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week

ACXP : 0.7200 (-16.63%)
BURU : 0.3601 (+32.93%)
ZAPP : 1.4500 (-0.68%)
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel...

ACXP : 0.7200 (-16.63%)
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 0.7200 (-16.63%)
Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as...

ACXP : 0.7200 (-16.63%)
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted...

ACXP : 0.7200 (-16.63%)
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 0.7200 (-16.63%)

Business Summary

Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y.

See More

Key Turning Points

3rd Resistance Point 1.0200
2nd Resistance Point 0.9600
1st Resistance Point 0.8400
Last Price 0.7200
1st Support Level 0.6600
2nd Support Level 0.6000
3rd Support Level 0.4800

See More

52-Week High 5.2800
Fibonacci 61.8% 3.5381
Fibonacci 50% 3.0000
Fibonacci 38.2% 2.4619
Last Price 0.7200
52-Week Low 0.7200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar